These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 34705051)
1. A bio-what? Medical companions' perceptions towards biosimilars and information needs in rheumatology. Gasteiger C; Scholz U; Petrie KJ; Dalbeth N Rheumatol Int; 2022 Nov; 42(11):1993-2002. PubMed ID: 34705051 [TBL] [Abstract][Full Text] [Related]
2. Is Three a Crowd? The Influence of Companions on a Patient's Decision to Transition to a Biosimilar. Gasteiger C; Groom KM; Lobo M; Scholz U; Dalbeth N; Petrie KJ Ann Behav Med; 2022 May; 56(5):512-522. PubMed ID: 34453530 [TBL] [Abstract][Full Text] [Related]
3. Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch. Gasteiger C; Lobo M; Dalbeth N; Petrie KJ Rheumatol Int; 2021 Jan; 41(1):163-171. PubMed ID: 32300866 [TBL] [Abstract][Full Text] [Related]
4. Using family-centered communication to optimize patient-provider-companion encounters about changing to biosimilars: A randomized controlled trial. Gasteiger C; Perera A; Yielder R; Scholz U; Dalbeth N; Petrie KJ Patient Educ Couns; 2023 Jan; 106():142-150. PubMed ID: 36400636 [TBL] [Abstract][Full Text] [Related]
5. "Biosimilar, so it looks alike, but what does it mean?" A qualitative study of Danish patients' perceptions of biosimilars. Varma M; Almarsdóttir AB; Druedahl LC Basic Clin Pharmacol Toxicol; 2022 May; 130(5):581-591. PubMed ID: 35261174 [TBL] [Abstract][Full Text] [Related]
6. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148 [TBL] [Abstract][Full Text] [Related]
7. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342 [TBL] [Abstract][Full Text] [Related]
8. Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey. Frantzen L; Cohen JD; Tropé S; Beck M; Munos A; Sittler MA; Diebolt R; Metzler I; Sordet C Joint Bone Spine; 2019 Jul; 86(4):491-496. PubMed ID: 30659920 [TBL] [Abstract][Full Text] [Related]
9. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey. Aladul MI; Fitzpatrick RW; Chapman SR BioDrugs; 2017 Oct; 31(5):439-446. PubMed ID: 28752242 [TBL] [Abstract][Full Text] [Related]
11. Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis. Kovitwanichkanont T; Raghunath S; Wang D; Kyi L; Pignataro S; Morton S; Morand E; Leech M Intern Med J; 2020 Mar; 50(3):374-377. PubMed ID: 32141205 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131 [TBL] [Abstract][Full Text] [Related]
14. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology]. Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629 [TBL] [Abstract][Full Text] [Related]
15. Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey. Kolbe AR; Kearsley A; Merchant L; Temkin E; Patel A; Xu J; Jessup A BioDrugs; 2021 May; 35(3):363-372. PubMed ID: 33826078 [TBL] [Abstract][Full Text] [Related]
16. Effects of Message Framing on Patients' Perceptions and Willingness to Change to a Biosimilar in a Hypothetical Drug Switch. Gasteiger C; Jones ASK; Kleinstäuber M; Lobo M; Horne R; Dalbeth N; Petrie KJ Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1323-1330. PubMed ID: 31233269 [TBL] [Abstract][Full Text] [Related]
17. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns? Gecse KB; Cumming F; D'Haens G Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783 [TBL] [Abstract][Full Text] [Related]
18. US rheumatologists' beliefs and knowledge about biosimilars: a survey. Gibofsky A; McCabe D Rheumatology (Oxford); 2021 Feb; 60(2):896-901. PubMed ID: 33146388 [TBL] [Abstract][Full Text] [Related]
19. The changing landscape of biosimilars in rheumatology. Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Physicians' Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing. Karateev D; Belokoneva N Biomolecules; 2019 Feb; 9(2):. PubMed ID: 30754705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]